Pharmacological effects and clinical evaluation of brivaracetam
10.13699/j.cnki.1001-6821.2017.15.034
- VernacularTitle:布瓦西坦的药理作用及临床评价
- Author:
Xue-Jiao HONG
1
;
Shu-Juan ZHAO
;
Yi-Meng WANG
;
Yu-Hua QIN
;
Hong-Wei ZHAO
Author Information
1. 河南省人民医院药学部
- Keywords:
brivaracetam;
antiepileptic drug;
pharmacokinetics;
pharmacodynamics
- From:
The Chinese Journal of Clinical Pharmacology
2017;33(15):1491-1493,1502
- CountryChina
- Language:Chinese
-
Abstract:
Brivaracetam is a selective,high-affinity synaptic vesicle protein 2A (SV2A) ligand,which was approved for the adjunctive treatment of 16 years of age and older patients with partial seizures.Brivaracetam is a structural analogues of levetiracetam,but has a 15-30 fold increased affinity for SV2A compared with levetiracetam.It works quickly through the blood-brain barrier and has less interaction with other drugs.This paper summarizes the research advances of brivaracetam on the pharmacodynamics,pharmacokinetics,drug interaction,toxicology,clinical research,security and use in specific population.The results can provide useful information for the treatment of antiepileptic therapy.
